5 recruiting, 4 active not recruiting, 4 terminated, 4 unknown. 13 Phase 1, 12 Phase 2, 1 Early Phase 1.
Follow B-cell Lymphoma Refractory: new trials by email Literature Review of B-cell Lymphoma Refractory trials Research Report on B-cell Lymphoma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas CART infusion - B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | National University Hospital, Singapore | 30 | 2026-03-02 | 2026-04-09 |
| Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia Polymer-Lipid Nanoparticle-Mediated Delivery of CD19/CD20 Dual-Targeting InViVoCAR1920 mRNA for CAR-T Cell Immunotherapy - B-cell Lymphoma Refractory | Phase 2 | Recruiting | Daihong Liu | 10 | 2025-09-01 | 2026-01-07 |
| Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma Leukapheresis, Bridging Therapy, Lymphodepletion - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Terminated | Universität Münster | 1 | 2025-03-13 | 2025-09-04 |
| CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells） - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission | Phase 1 | Recruiting | Rong Tao | 48 | 2024-05-31 | 2024-06-06 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma autologous NK cell - NK Cell, B-cell Lymphoma Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Xiangyang No.1 People's Hospital | 33 | 2023-07-01 | 2023-06-22 |
| Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies Cyclophosphamide, Fludarabine, Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 - Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory | Phase 1 | Recruiting | Nelson Hamerschlak | 30 | 2023-02-07 | 2025-09-25 |
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1 / Phase 2 | Terminated | Mustang Bio | 20 | 2022-05-24 | 2024-07-22 |
| Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma LCAR-AIO cells product - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 14 | 2022-03-14 | 2025-06-03 |
| Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells - B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory | Phase 2 | Active not recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 28 | 2022-02-01 | 2025-07-17 |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | Mustang Bio | 3 | 2021-09-29 | 2024-07-22 | |
| Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation axicabtagene ciloleucel - B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Active not recruiting | The Lymphoma Academic Research Organisation | 62 | 2021-03-10 | 2026-03-27 |
| Induced-T Cell Like NK Cells for B Cell Malignancies CAR-ITNK cells - B Cell Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 12 | 2021-01-29 | 2021-02-10 |
| CAR T Cell Therapy Related Cardiovascular Outcomes Cardiovascular Diseases, B-cell Acute Lymphoblastic Leukemia | Completed | University College London Hospitals | 150 | 2021-01-18 | 2023-05-12 | |
| A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma Orelabrutinib, Recombinant humanized monoclonal antibody MIL62 injection - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 43 | 2020-07-28 | 2024-02-07 |
| CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL CD19 and CD22 targeted CAR-T cells - B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Early Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 30 | 2020-05-01 | 2020-03-11 |
| CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Fludarabine, Cyclophosphamide, CD19-CD34 CAR transduced T cells - B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory | Phase 1 | Active not recruiting | Loyola University | 24 | 2019-12-31 | 2022-08-15 |
| MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) MB-CART19.1 - Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent | Phase 1 | Active not recruiting | Miltenyi Biomedicine GmbH | 48 | 2018-11-26 | 2026-10-09 |
| MB-CART20.1 Lymphoma MB-CART20.1 - Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Miltenyi Biomedicine GmbH | 10 | 2018-09-25 | 2024-11-21 |
| Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas Thiotepa, Busulfan, Fludarabin - B-cell Lymphoma Refractory | Phase 2 | Unknown | Azienda Ospedaliera San Giovanni Battista | 42 | 2013-02-01 | 2014-07-08 |
Showing 20 of 21. Sign in to see all of them.
Burkitt Lymphoma (4) · Lymphoma, B-Cell (3) · Recurrence (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Cardiotoxicity (1) · Cardiovascular Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Hairy Cell (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Hematologic Diseases (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Leukemia (5) · Leukemia, Lymphoid (5) · DNA Virus Infections (4) · Epstein-Barr Virus Infections (4) · Herpesviridae Infections (4)
Cyclophosphamide (2) · axicabtagene ciloleucel (2) · fludarabine (2) · Antigens, CD19 (1) · Blood Component Removal (1) · Busulfan (1) · Carboplatin (1) · Cyclosporine (1) · Cytoreduction Surgical Procedures (1) · Dexamethasone (1) · Etoposide (1) · Hematocrit (1) · Ifosfamide (1) · Immunosuppression Therapy (1) · Inotuzumab Ozogamicin (1)
Miltenyi Biomedicine GmbH (2) · Mustang Bio (2) · Azienda Ospedaliera San Giovanni Battista (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Cristiana Sessa (1) · Daihong Liu (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Loyola University (1) · Nanfang Hospital, Southern Medical University (1) · National University Hospital, Singapore (1) · Nelson Hamerschlak (1) · Rong Tao (1) · Samsung Medical Center (1) · The Lymphoma Academic Research Organisation (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (8) · Germany (3) · United States (3) · Belgium (1) · Brazil (1) · France (1) · Italy (1) · Singapore (1) · South Korea (1) · Switzerland (1) · United Kingdom (1)
Anastasios Stathis, Dr. (1) · Benedetto Bruno, MD (1) · Bin Pei (1) · Bruce Dezube, M.D. (1) · Georg Lenz, Prof (1) · Mazyar Shadman, MD (1) · Michelle Poon (1) · Nasheed Hossain, MD (1) · Nelson Hamerschlak, MD, PhH (1) · Peter Borchmann, Prof. Dr. (1) · Qi-fa Liu (1) · Roch Houot, PhD (1) · Rong Tao, MD (1)
PMID 20660832, PMID 24876563, PMID 26755709, PMID 28925994, PMID 29155426, PMID 29419431, PMID 29437609, PMID 30501490, PMID 30518502, PMID 30592986, PMID 31056762, PMID 31723828, PMID 32278358, PMID 33147337, PMID 33512414, PMID 34041526, PMID 34312556, PMID 34407735, PMID 34642489, PMID 37710005, PMID 41512176
2017 (1), R44CA265616 (1)